{"version":"1.0","provider_name":"v99news.com","provider_url":"https:\/\/v99news.com","author_name":"vrtechllc98","author_url":"https:\/\/v99news.com\/author\/vrtechllc98\/","title":"Hulio: Biosimilar Humira likely to boost US revenues for Biocon Biologics - v99news.com","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"B20RB5vayb\"><a href=\"https:\/\/v99news.com\/hulio-biosimilar-humira-likely-to-boost-us-revenues-for-biocon-biologics\/\">Hulio: Biosimilar Humira likely to boost US revenues for Biocon Biologics<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/v99news.com\/hulio-biosimilar-humira-likely-to-boost-us-revenues-for-biocon-biologics\/embed\/#?secret=B20RB5vayb\" width=\"600\" height=\"338\" title=\"&#8220;Hulio: Biosimilar Humira likely to boost US revenues for Biocon Biologics&#8221; &#8212; v99news.com\" data-secret=\"B20RB5vayb\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/i0.wp.com\/bsmedia.business-standard.com\/_media\/bs\/img\/article\/2021-09\/17\/full\/1631878498-1779.jpeg?fit=600%2C99999&ssl=1","thumbnail_width":false,"thumbnail_height":false,"description":"&#13; Biocon Biologics (BBL) launched Hulio, a biosimilars version of Abbvie\u2019s blockbuster drug Humira, in the US, a market that is already getting crowded with several biosimilars. &#13; Analysts, however, feel that together with upcoming Aspart (insulin) and vaccines, Hulio will help drive BBL\u2019s revenues from the current $1 billion to around $1.65 billion by [&hellip;]"}